Edward Feener - Chief Scientific Officer, Kalvista Pharmaceuticals, Inc

As of August 4, 2021


Edward Feener Net Worth

  • Net worth is estimated to be at least $4.75M
  • Owns at least 8,234 units of Kalvista Pharmaceuticals, Inc stock
  • Sold an estimated value of $2.93M in the last 4 years at Kalvista Pharmaceuticals, Inc

Edward Feener Trading

  • Largest purchase of shares was 6,000 units , worth over $61.26K on May 6, 2021
  • Largest sale of shares was 31,000 units , worth over $1.04M on February 25, 2021
  • In total has made about 18 transactions over 4 years
  • Usually trades in May, with the busiest year in 2021
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Edward Feener Mailing Address

  • Mailing address is One Kendall Square, Building 200 Suite 2203 Cambridge MA 02139 MA

Kalvista Pharmaceuticals, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Compensation
Total
T. Andrew Crockett 2021 $556,120 $458,799 - $1,281,708 $11,400 $2,308,027
T. Andrew Crockett 2020 $556,120 $229,400 - $1,163,160 $11,882 $1,960,562
T. Andrew Crockett 2019 $505,000 $353,500 - $2,418,444 $11,000 $3,287,944
Benjamin L. Palleiko 2021 $435,000 $261,000 - $747,663 $15,850 $1,459,513
Benjamin L. Palleiko 2020 $435,000 $156,600 - $581,580 $11,900 $1,185,080
Benjamin L. Palleiko 2019 $366,000 $192,150 $527,794 $994,555 $11,000 $2,091,499
Christopher M. Yea 2021 $420,000 $252,000 - $712,060 $25,341 $1,409,401
Christopher M. Yea 2020 $420,000 $117,600 - $480,773 $25,271 $1,094,044
Christopher M. Yea 2019 $341,093 $174,596 - $891,350 $20,466 $1,427,505
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1348911/000119312521249158/d191826ddef14a.htm

Kalvista Pharmaceuticals, Inc Insider Trading

  • The most recent transaction was 5,000 units sold on August 4, 2021 by Christopher Yea worth over $102.58K
  • In the last 4 years, insiders at Kalvista Pharmaceuticals, Inc sold an estimated value of $74.99M and bought an estimated value of $43.76M
  • The most active traders are Andrew Thomas Crockett, CEO,  Christopher Yea, Chief Development Officer,  and Edward Feener, Chief Scientific Officer
  • Insider trading is most common in October, with the busiest year in 2019

KalVista Pharmaceuticals, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1